MedTrace Logo

Nutrition, Oral Health and Type 2 Diabetes

NCT02916589 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2018-09-27

No results posted yet for this study

Summary

Obesity continues to pose major public health challenges worldwide with cardiovascular damage, hypertension and diabetes as possible subsequent conditions. The obese are at risk for mortality and morbidity as they suffer from a high level of immune sensitivity with consequences related to damage to the circulation and microvasculature. The immune process itself is modulated by cytokines, which are small proteins which can modulate the spectrum of the inflammatory process. These proteins may act as biomarkers in the mouth.

Diabetes is also a consequence of sustained obesity and this condition can strongly influence immune status. Diabetes is characterized by the failure to produce the hormone insulin or a loss of sensitivity to insulin. Without insulin high blood glucose results in the release of a series of pro-inflammatory factors, which lead to pathological processes in several organs leading to high mortality and morbidity. Periodontitis, a common complication of diabetes, is an inflammatory condition of the soft tissue of the periodontium, causing alveolar bone loss. The accessibility of the oral cavity facilitates the study of early inflammatory processes.

Changes in diet may reduce inflammation, controlling gingival inflammation as well as clinical treatment. Since 2004 Igelösa Life Science AB has developed a modified Nordic diet based on evidence, primarily from the Japanese island of Okinawa, where the world's oldest and most healthy people live. In this study we will investigate the association between Igelösa dietary intake and measurements of inflammation in 30 overweight individuals with or without other systemic diseases.

Conditions

Interventions

DIETARY_SUPPLEMENT

Diet

Sponsors & Collaborators

  • Kristianstad University

    lead OTHER

Principal Investigators

  • Brita Larsson · Kristianstad University

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-09-30
Primary Completion
2016-12-31
Completion
2018-07-31

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02916589 on ClinicalTrials.gov